Zura Bio Appoints Eric Hyllengren as New CFO Amid Verender Badial's Departure

Zura Bio has appointed Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down and remain with the company through July 31, 2025. Hyllengren brings over 20 years of financial leadership experience in the life sciences and biotechnology sectors. He previously worked at Amgen and Atara Biotherapeutics.

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, has announced the appointment of Eric Hyllengren as Chief Financial Officer (CFO), effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transition [1].

Eric Hyllengren brings over 20 years of financial leadership experience in the life sciences and biotechnology sectors. He most recently served as Chief Operating Officer and Chief Financial Officer at Atara Biotherapeutics, where he led strategic finance, capital markets, operational planning, investor relations, controllership, business development, alliance management, legal, and information technology. At Atara, he played a key role in advancing capital strategy, driving cost transformation, and supporting organizational design [1].

Prior to Atara, Hyllengren spent 15 years at Amgen in roles spanning corporate finance, investor relations, business development, and alliance management, supporting global operations and long-range planning [1]. His broad experience is expected to support Zura Bio’s ongoing growth and operational execution.

“I am excited to welcome Eric to our leadership team,” said Robert Lisicki, Chief Executive Officer of Zura Bio. “His broad financial expertise, combined with deep sector experience, makes him a strong strategic partner. We’re confident he will elevate our leadership team and continue building the strong relationships we’ve established with our stakeholders as we pursue our long-term goals” [1].

Verender Badial, who joined Zura Bio in March 2023, led the development of Zura Bio’s internal financial and operational systems, contributed to shaping its financial strategy, and participated in capital-raising efforts that supported the company’s early growth [1]. He commented, “Being part of Zura Bio’s mission has been both rewarding and meaningful. I am proud of what we’ve accomplished and grateful to have worked alongside such talented and dedicated colleagues. I look forward to supporting a smooth transition” [1].

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases. The Company’s pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients [1].

For more information, please visit [www.zurabio.com](http://www.zurabio.com).

References:
[1] https://www.businesswire.com/news/home/20250701021645/en/Zura-Bio-Announces-Chief-Financial-Officer-Transition